...
首页> 外文期刊>American journal of therapeutics >Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease
【24h】

Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease

机译:VEGFR-2基因多态性与冠心病患者氯吡格雷抗性的关系

获取原文
获取原文并翻译 | 示例
           

摘要

Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a central role in atherogenesis. We investigated the correlation between VEGFR-2 polymorphisms and the risk of clopidogrel resistance (CR) in patients with coronary heart disease (CHD). The study involved 275 patients with CHD undergoing percutaneous coronary intervention and on antiplatelet clopidogrel therapy. The participants were divided into CR group (n = 59) and non-CR group (NCR, n = 216) based on maximum platelet aggregation measurements. VEGFR-2 gene polymorphisms, +1192C>T (rs2305948), +1416T>A (rs1870377), and -271A>G (rs7667298), were genotyped using polymerase chain reaction-restriction fragment length polymorphism. Enzyme-linked immunosorbent assay was used to measure serum transforming growth factor, beta receptor 2 levels. CR was found in 59 patients (20.45%). A significantly higher proportion of patients in the CR group had a history of diabetes mellitus compared with the NCR group (P < 0.05). Genotype and allele frequency of VEGFR-2 +1192C>T (rs2305948) was significantly higher in the CR group than in the NCR group (all P < 0.01). In the VEGFR-2 +1192C>T (rs2305948), the angina pectoris, recurrent myocardial infarction, and combined end point events were significantly more prevalent in the TT carriers than in the CC + CT carriers. In VEGFR-2 -271A>G (rs7667298), the GG carriers had a lower proportion of target lesion revascularization and angina pectoris in contrast to the AA + AG carriers (all P < 0.05). Based on our results, VEGFR-2 +1192C>T (rs2305948) polymorphism is strongly associated with increased CR and main adverse cardiovascular event incidence in patients with CHD undergoing percutaneous coronary intervention. Additionally, patients with CHD with diabetes mellitus history were more likely to develop CR. The associations of +1416T>A (rs1870377) and -271A>G (rs7667298) polymorphisms with CR were inconclusive and will need to be examined further.
机译:血管内皮生长因子受体2(VEGFR-2)在血液发生中起着重要作用。我们研究了VEGFR-2多态性与冠心病(CHD)患者患者氯吡格雷抗性(CR)之间的相关性。该研究涉及275例CHD患者进行经皮冠状动脉干预和抗血小板氯吡格雷治疗。基于最大血小板聚集测量,参与者分为Cr组(n = 59)和非Cr组(NCR,N = 216)。 VEGFR-2基因多态性,+ 1192C> T(RS2305948),+ 1416T> A(RS1870377)和-271A> G(RS7667298)是使用聚合酶链反应限制性片段长度多态性进行基因分型。酶联免疫吸附测定用于测量血清转化生长因子,β受体2水平。在59名患者中发现了CR(20.45%)。与NCR组相比,CR组患者的显着较高比例的患者患有糖尿病的历史(P <0.05)。 VEGFR-2 + 1192C> T(RS2305948)的基因型和等位基因频率在CR组中显着高于NCR组(所有P <0.01)。在VEGFR-2 + 1192C> T(RS2305948)中,在TT载体中,心绞痛,复发性心肌梗死和组合的终点事件比CC + CT载体在TT载体中显着普遍。在VEGFR-2 -271A> G(RS7667298)中,GG载体与AA + AG载体相比(所有P <0.05)的靶病变血运重建和心绞痛的比例较低。基于我们的结果,VEGFR-2 + 1192C> T(RS2305948)多态性与CHD经皮冠状动脉介入的CHD患者的CR和主要不良心血管事件发生率强烈相关。此外,患有糖尿病患者的患者患者历史更可能发展CR。 + 1416T> A(RS1870377)和-271A> G(RS7667298)与Cr的多态性的关联是不确定的,需要进一步检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号